EIC Accelerator Challenge: Novel biomarker-based assays to guide personalised cancer treatment

Closed

Status as published by the data source.

Sign in to bookmark this

Scope:This EIC Accelerator Challenge aims to improve the efficacy, safety and uptake of therapeutic approaches against refractory cancers, using novel comprehensive predictive, prognostic and companion diagnostic tests, in the context of precision oncology.
The overall goal of this Challenge is to support and accelerate the preclinical validation and/or clinical phase 1 work carried out by innovative SMEs (including start-ups, spinouts) and small midcaps to develop novel predictive, prognostic and companion diagnostic assays to guide cancer treatment. This Challenge has the following specific objectives:

• to develop novel companion diagnostic assays, including through liquid profiling to identify who, among cancer patients, is more likely to benefit from a given treatment (guided treatment);
• to develop novel predictive biomarker-based assays to identify who, among patients with potentially precancerous lesions, is more likely to develop cancer;
• to develop novel prognostic assays including through liquid profiling to identify who, among the cancer patients who underwent treatment, is more likely to recur;
• to develop novel companion diagnostic assays, including through liquid profiling to identify who, among the cancer patients receiving treatment, is more likely to develop side effects as a result of the treatment and,
• to develop novel monitoring biomarker-based assays to effectively monitor the clinical course of the disease. As expected outcomes from this Challenge, clinicians will be able to:

• Identify, who among cancer patients, is more likely to benefit from a given treatment (guided treatment),
• Identify, who among patients with potentially precancerous lesions, is more likely to develop cancer,
• Identify, who among the cancer patients having underwent treatment, is more likely to recur,
• Identify who among the cancer patients receiving treatment, is more likely to develop side effects as a result of the treatment, affecting their quality of life and
• More effectively monitor the clinical course of the disease. For further information, please see the EIC Work Programme 2023.

Status

Closed

Deadline

8 November 2023 (time not stated)

Opens

7 December 2022

Published

7 December 2022

Grant range

€500,000 – €17,500,000

Country

European Union (EU-wide)

Programme

Horizon Europe (HORIZON)

Official page

Open at the source portal

Other calls under Horizon Europe (HORIZON)

• PV based electrification of the economy: Designing & optimising PV systems supporting industrial electrification and promoting participation in electricity markets (EUPI-PV Partnership)Forthcoming · deadline 1 December 2027 · European Union (EU-wide) · €18,000,000
• Advanced TSO control rooms to enhance grid observability, stability and resilienceForthcoming · deadline 1 December 2027 · European Union (EU-wide) · €28,500,000
• Advanced Distribution Management Systems (ADSM) for more efficient and flexible distribution gridsForthcoming · deadline 1 December 2027 · European Union (EU-wide) · €28,500,000
• Community of practice - Data-Driven Decision-Making in EnergyForthcoming · deadline 1 December 2027 · European Union (EU-wide) · €6,000,000
• Industrial processes and equipment for innovative, reliable and scalable tandem technologies (EUPI-PV Partnership)Forthcoming · deadline 1 December 2027 · European Union (EU-wide) · €28,500,000
• Integrated Approaches for Retrofitting Infrastructures with Innovative Energy Storage TechnologiesForthcoming · deadline 1 December 2027 · European Union (EU-wide) · €22,500,000
• Demonstration of hydropower technologies for efficient and forward-looking refurbishment of existing hydropower plantsForthcoming · deadline 1 December 2027 · European Union (EU-wide) · €17,000,000
• Delivery of industrial CCUS clusters – Societal Readiness pilotForthcoming · deadline 1 December 2027 · European Union (EU-wide) · €30,000,000

All calls under this programme

Similar opportunities

• EIC Accelerator 2026 - Short proposalOpen · deadline 17 December 2026 · European Union (EU-wide) · same sector, same funder
• Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypesForthcoming · deadline 21 September 2027 · European Union (EU-wide) · €24,000,000 · same funder, same programme
• Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancersOpen · deadline 15 September 2026 · European Union (EU-wide) · €22,186,000 · same funder, same programme
• Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseasesForthcoming · deadline 13 April 2027 · European Union (EU-wide) · €44,200,000 · same funder, same programme
• Microbiome for early cancer prediction before the onset of diseaseOpen · deadline 15 September 2026 · European Union (EU-wide) · €15,000,000 · same funder, same programme
• EIC Accelerator Challenge: Customer-driven, innovative space technologies and servicesClosed · deadline 8 November 2023 · European Union (EU-wide) · €17,500,000 · same sector, same funder